The value of choosing the “right” indication for phase 2a

Even if your company is not planning to develop a pipeline asset through phase 3, you’re significantly more likely to secure a favorable deal with a pharma partner if you deliver relevant phase 2a data in a commercially viable indication. … Continue reading